267.40
price up icon2.42%   6.33
pre-market  Vorhandelsmarkt:  267.51   0.11   +0.04%
loading
Schlusskurs vom Vortag:
$261.07
Offen:
$261.92
24-Stunden-Volumen:
1.34M
Relative Volume:
1.48
Marktkapitalisierung:
$39.21B
Einnahmen:
$5.02B
Nettoeinkommen (Verlust:
$1.31B
KGV:
30.01
EPS:
8.91
Netto-Cashflow:
$1.56B
1W Leistung:
+6.11%
1M Leistung:
+5.41%
6M Leistung:
+8.11%
1J Leistung:
+29.00%
1-Tages-Spanne:
Value
$261.06
$268.65
1-Wochen-Bereich:
Value
$250.18
$268.65
52-Wochen-Spanne:
Value
$196.43
$268.65

Resmed Inc Stock (RMD) Company Profile

Name
Firmenname
Resmed Inc
Name
Telefon
(858) 746-2400
Name
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Name
Mitarbeiter
9,980
Name
Twitter
@resmed
Name
Nächster Verdiensttermin
2024-10-24
Name
Neueste SEC-Einreichungen
Name
RMD's Discussions on Twitter

Vergleichen Sie RMD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Instruments & Supplies icon
RMD
Resmed Inc
267.40 36.95B 5.02B 1.31B 1.56B 8.91
Medical Instruments & Supplies icon
ISRG
Intuitive Surgical Inc
511.00 183.59B 8.71B 2.48B 1.75B 6.82
Medical Instruments & Supplies icon
BDX
Becton Dickinson Co
181.28 51.10B 20.87B 1.50B 2.59B 5.24
Medical Instruments & Supplies icon
ALC
Alcon Inc
88.66 42.51B 9.93B 1.12B 1.58B 2.25
Medical Instruments & Supplies icon
WST
West Pharmaceutical Services Inc
218.90 15.88B 2.90B 467.20M 306.90M 6.37

Resmed Inc Stock (RMD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-15 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2025-03-19 Eingeleitet Morgan Stanley Overweight
2025-01-16 Eingeleitet Goldman Buy
2025-01-10 Eingeleitet Piper Sandler Neutral
2024-12-13 Eingeleitet Stifel Hold
2024-09-24 Eingeleitet Robert W. Baird Outperform
2024-09-18 Herabstufung Wolfe Research Peer Perform → Underperform
2024-09-04 Herabstufung Needham Buy → Hold
2024-06-25 Herabstufung Oppenheimer Outperform → Perform
2024-06-24 Herabstufung Citigroup Buy → Neutral
2024-02-06 Fortgesetzt KeyBanc Capital Markets Overweight
2023-10-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2023-10-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2023-10-09 Hochstufung JP Morgan Neutral → Overweight
2023-09-29 Herabstufung Wolfe Research Outperform → Peer Perform
2023-09-06 Hochstufung Needham Hold → Buy
2023-09-05 Herabstufung UBS Buy → Neutral
2023-08-01 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2023-05-23 Eingeleitet UBS Buy
2023-04-14 Eingeleitet Mizuho Buy
2023-01-17 Hochstufung JP Morgan Neutral → Overweight
2022-10-28 Herabstufung Citigroup Buy → Neutral
2022-10-20 Hochstufung BofA Securities Neutral → Buy
2022-10-12 Eingeleitet Jefferies Hold
2022-09-08 Hochstufung Citigroup Neutral → Buy
2022-08-15 Herabstufung CLSA Buy → Outperform
2022-08-12 Herabstufung Citigroup Buy → Neutral
2022-08-12 Herabstufung JP Morgan Overweight → Neutral
2022-08-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-06-06 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2022-04-06 Eingeleitet Wolfe Research Outperform
2022-01-31 Hochstufung Citigroup Neutral → Buy
2022-01-31 Hochstufung Goldman Neutral → Buy
2022-01-28 Hochstufung RBC Capital Mkts Underperform → Sector Perform
2022-01-24 Hochstufung BofA Securities Underperform → Neutral
2022-01-24 Hochstufung JP Morgan Neutral → Overweight
2022-01-13 Hochstufung CLSA Outperform → Buy
2022-01-13 Hochstufung Robert W. Baird Neutral → Outperform
2021-12-21 Hochstufung KeyBanc Capital Markets Sector Weight → Overweight
2021-12-06 Hochstufung Macquarie Neutral → Outperform
2021-10-22 Hochstufung CLSA Underperform → Outperform
2021-08-02 Herabstufung CLSA Outperform → Sell
2021-08-02 Herabstufung Needham Buy → Hold
2021-07-28 Hochstufung Jefferies Underperform → Hold
2021-07-26 Herabstufung JP Morgan Overweight → Neutral
2021-07-14 Eingeleitet RBC Capital Mkts Underperform
2021-06-28 Herabstufung Citigroup Buy → Neutral
2021-06-22 Hochstufung Macquarie Neutral → Outperform
2021-06-22 Eingeleitet Robert W. Baird Neutral
2021-06-21 Bestätigt Needham Buy
2021-06-16 Herabstufung BofA Securities Neutral → Underperform
2021-06-09 Hochstufung CLSA Sell → Outperform
2021-05-21 Hochstufung JP Morgan Neutral → Overweight
2021-05-11 Hochstufung Citigroup Neutral → Buy
2021-04-30 Herabstufung Citigroup Buy → Neutral
2021-03-16 Hochstufung Needham Hold → Buy
2020-11-02 Hochstufung UBS Neutral → Buy
2020-10-30 Hochstufung JP Morgan Underweight → Neutral
2020-10-27 Hochstufung BofA Securities Underperform → Neutral
2020-08-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-06-17 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-05-01 Herabstufung JP Morgan Neutral → Underweight
2020-05-01 Hochstufung Oppenheimer Perform → Outperform
2020-02-18 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-02-03 Eingeleitet CLSA Underperform
2020-01-31 Herabstufung UBS Buy → Neutral
2020-01-10 Eingeleitet Oppenheimer Perform
2019-11-22 Eingeleitet KeyBanc Capital Markets Sector Weight
2019-07-29 Hochstufung UBS Neutral → Buy
2019-07-16 Herabstufung UBS Buy → Neutral
2019-05-06 Hochstufung UBS Neutral → Buy
2019-04-18 Hochstufung JP Morgan Underweight → Neutral
2019-01-25 Herabstufung Goldman Buy → Neutral
2019-01-25 Herabstufung JP Morgan Neutral → Underweight
2018-10-26 Hochstufung Credit Suisse Neutral → Outperform
2018-07-02 Eingeleitet Goldman Buy
Alle ansehen

Resmed Inc Aktie (RMD) Neueste Nachrichten

pulisher
Jul 22, 2025

What analysts say about ResMed Inc. stockSkyrocketing investment returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is ResMed Inc. a good long term investmentMarket-beating returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

ResMed Inc. Stock Analysis and ForecastMarket-leading capital gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives ResMed Inc. stock priceConsistently high returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

ResMed stock hits 52-week high at 263.62 USD By Investing.com - Investing.com South Africa

Jul 22, 2025
pulisher
Jul 21, 2025

Sleep Apnea Devices Market is expected to generate a revenue of USD 14.59 Billion by 2031, Globally, at 10.42 % CAGR: Verified Market Research® - GlobeNewswire Inc.

Jul 21, 2025
pulisher
Jul 19, 2025

Published on: 2025-07-19 18:08:41 - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

What makes ResMed Inc. stock attractive to long term investorsTrend Based Entry Alerts - beatles.ru

Jul 19, 2025
pulisher
Jul 17, 2025

This ResMed Insider Reduced Their Stake By 72% - simplywall.st

Jul 17, 2025
pulisher
Jul 17, 2025

This Pick Withstood the GLP-1 Challenge. Stick With the Stock. - Barron's

Jul 17, 2025
pulisher
Jul 16, 2025

Analyst Expectations For ResMed's Future - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

ResMed (RMD) Price Target Increased to $270 by Mizuho Analyst | - GuruFocus

Jul 16, 2025
pulisher
Jul 16, 2025

Brokers Set Expectations for ResMed's Q1 Earnings (NYSE:RMD) - MarketBeat

Jul 16, 2025
pulisher
Jul 15, 2025

RBC Upgrades ResMed to Outperform From Sector Perform, Adjusts Price Target to $294 From $255 - MarketScreener

Jul 15, 2025
pulisher
Jul 14, 2025

ResMed's Trading Volume Surges 78.7% to 2.35 Billion, Stock Price Drops 0.11% Placing 406th in Market Rankings - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly - 富途牛牛

Jul 14, 2025
pulisher
Jul 09, 2025

ResMed CEO Executes Stock Transactions Under Rule 10b5-1 Plan - TipRanks

Jul 09, 2025
pulisher
Jul 09, 2025

Resmed CEO Farrell sells $2.06 million in stock By Investing.com - Investing.com Canada

Jul 09, 2025
pulisher
Jul 09, 2025

Resmed Insider Sold Shares Worth $2,056,076, According to a Recent SEC Filing - MarketScreener

Jul 09, 2025
pulisher
Jul 07, 2025

ResMed Inc. Officer Plans Sale of Common Stock Under Rule 144 - TipRanks

Jul 07, 2025
pulisher
Jul 05, 2025

With 75% institutional ownership, ResMed Inc. (NYSE:RMD) is a favorite amongst the big guns - simplywall.st

Jul 05, 2025
pulisher
Jul 03, 2025

ResMed CFO Reports Changes in Stock Ownership - TipRanks

Jul 03, 2025
pulisher
Jul 03, 2025

ResMed to Release Q4 2025 Financial Results on July 31, 2025, via Webcast - AInvest

Jul 03, 2025
pulisher
Jul 02, 2025

ResMed Executives Sell Shares Under Pre-arranged Trading Plans - TradingView

Jul 02, 2025
pulisher
Jul 02, 2025

ResMed Director Announces Further Share Sale - TipRanks

Jul 02, 2025
pulisher
Jul 01, 2025

ResMed Chief Legal Officer Sells Shares - MarketScreener

Jul 01, 2025
pulisher
Jul 01, 2025

Resmed Inc Officer Files Notice for Stock Sale Under Rule 144 - TipRanks

Jul 01, 2025
pulisher
Jul 01, 2025

Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025 | RMD Stock News - GuruFocus

Jul 01, 2025
pulisher
Jul 01, 2025

Resmed Announces Fourth Quarter Fiscal Year 2025 Financial Results Release and Webcast Details - Quiver Quantitative

Jul 01, 2025
pulisher
Jul 01, 2025

ResMed (NYSE:RMD) Shows Growth in ROCE and Business Efficiency NYSE Composite - Kalkine Media

Jul 01, 2025
pulisher
Jul 01, 2025

ResMed (NYSE:RMD) Could Become A Multi-Bagger - Yahoo Finance

Jul 01, 2025
pulisher
Jun 26, 2025

Zacks.com featured highlights Sprouts Farmers Market, Adobe, GE Aerospace and ResMed - Yahoo Finance

Jun 26, 2025
pulisher
Jun 25, 2025

All You Need to Know About ResMed (RMD) Rating Upgrade to Buy - Yahoo Finance

Jun 25, 2025
pulisher
Jun 19, 2025

Is the ResMed share price still cheap? What the numbers say - The Motley Fool Australia

Jun 19, 2025
pulisher
Jun 18, 2025

ResMed’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance

Jun 18, 2025
pulisher
Jun 17, 2025

Bi Level Automatic Ventilator Market Is Booming Worldwide 2025-2032 | ResMed Inc., Philips Healthcare, Medtronic Plc - openPR.com

Jun 17, 2025
pulisher
Jun 16, 2025

ResMed Stock: Is RMD Outperforming the Healthcare Sector? - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

ResMed Inc. (RMD) Investor Outlook: Analyzing Growth Potential Amidst a 6% Upside - DirectorsTalk Interviews

Jun 16, 2025
pulisher
Jun 16, 2025

ResMed Stock: Is RMD Outperforming The Healthcare Sector? - Barchart.com

Jun 16, 2025
pulisher
Jun 10, 2025

Resmed CEO Michael Farrell sells shares worth $2.01 million By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

ResMed: A Mixed Bag for Investors Amid Rising Competition - The Globe and Mail

Jun 10, 2025
pulisher
Jun 10, 2025

Resmed CEO Michael Farrell sells shares worth $2.01 million - Investing.com

Jun 10, 2025
pulisher
Jun 09, 2025

ResMed CEO Sells Shares Worth $2 Million - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

ResMed Inc Reports Change in Beneficial Ownership - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

ResMed: A Sleeping Giant Hiding In Plain Sight (NYSE:RMD) - Seeking Alpha

Jun 09, 2025
pulisher
Jun 08, 2025

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell? - MSN

Jun 08, 2025
pulisher
Jun 06, 2025

Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

ResMed director Peter Farrell sells $494,640 in stock By Investing.com - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

ResMed director Peter Farrell sells $494,640 in stock - Investing.com Australia

Jun 06, 2025

Finanzdaten der Resmed Inc-Aktie (RMD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
medical_instruments_supplies ALC
$88.66
price up icon 1.72%
medical_instruments_supplies BDX
$181.28
price up icon 3.39%
medical_instruments_supplies WST
$218.90
price up icon 4.20%
medical_instruments_supplies COO
$73.03
price up icon 2.40%
$65.37
price up icon 2.64%
Kapitalisierung:     |  Volumen (24h):